Results 181 to 190 of about 21,384 (315)

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Cold‐Adapted Lipid A from Polaribacter sp. SM1127: A Study of Structural Heterogeneity and Immunostimulatory Properties

ChemBioChem, EarlyView.
This analysis reveals structural heterogeneity in the lipopolysaccharide lipid A from the cold‐adapted Gram‐negative bacterium Polaribacter sp. SM1127, with variations in fatty acid chain number, length, branching, saturation, and hydroxylation degree, likely aiding bacterial adaptation to cold environmental stressors. Lipopolysaccharide is shown to be
Roberta Cirella, Emanuela Andretta, Luca De Simone Carone, Francesca Olmeo, Mei‐Ling Sun, Yu‐Zhong Zhang, Marcello Mercogliano, Antonio Molinaro, Alba Silipo, Flaviana Di Lorenzo   +9 more
wiley   +1 more source

Night‐Time Chronotherapy with Methylprednisolone Prevents an Acute Rejection in Pediatric Patients with Liver Transplantation: A Randomized Clinical Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Concept of methylprednisolone chronotherapy to prevent acute rejections. While endogenous cortisol secretion rises in the early morning, the number of lymphocytes in the blood is higher at night, thus exhibiting an antiphase pattern to cortisol secretion. Therefore, compared with the daytime, the infiltration of lymphocytes into immune‐reactive tissues
Kentaro Ushijima, Yukihiro Sanada, Shinya Otomo, Keiko Ogaki, Taiichi Wakiya, Noriki Okada, Yuta Hirata, Yasuharu Onishi, Yasunaru Sakuma, Yukiyo Wada, Akio Fujimura, Koichi Mizuta   +11 more
wiley   +1 more source

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

Clinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou, Rohit Rao, Monica E. Shapiro, Nessy Tania, Cody Herron, Cynthia J. Musante, Jim H. Hughes   +6 more
wiley   +1 more source

Think highly of immunoglobulin G4‐related chronic rhinosinusitis as a clinical entity in immunoglobulin G4‐related disease

Eye &ENT Research, EarlyView.
Abstract IgG4‐related chronic rhinosinusitis (IgG4‐related CRS) is gaining recognition among various specialized physicians. As a systemic disease involving multiple organs, IgG4‐related CRS is still not widely recognized as an independent clinical entity. Given the complexity of diagnosing autoimmune‐related multisystem diseases, early recognition and
Lianqi Wan, Luo Zhang, Yingshi Piao, Yuan Zhang   +3 more
wiley   +1 more source

Transient pain and long-term gain: adjuvant dose directs immune memory. [PDF]

J Clin Invest
Pal PB, Iyer SS.
europepmc   +1 more source

Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology

, 2020
Kaufmann, S.
core   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source